Tag Archives: Joe Panetta

Putting the M Back in M&A

Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from […]
Posted in Agency Insight, Biotech, Deals, FDA | Also tagged , , | Leave a comment
  • Categories

  • Meta